Highlights of the important and interesting in the world of healthcare:
Directors: cough up the cash. Remember last week’s $600 million Department of Justice settlement by Botox maker Allergan? A shareholder has filed a lawsuit claiming the Allergan board should pay the fine, according to the Pharmalot blog.
Embryonic stem cell injunction stays. A federal judge on Tuesday denied an Obama administration motion to lift an injunction he issued two weeks ago barring the government from funding research involving human embryonic stem cells, according to the Washington Post. However, the judge said his injunction is less restrictive than the administration thinks.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
What cost defensive medicine? How much do we spend on all those extra tests and procedures doctors perform to protect themselves from lawsuits? A Health Affairs study suggests we’re paying less than we think, NPR reports.
Man, I’ve got a headache. Rather than landfill millions of bottles of recalled children’s Tylenol, Johnson & Johnson CEO Bill Weldon may be able to donate them to kill snakes in Guam, says Pharmalot blogger Ed Silverman.
An ounce of prevention… Preventive health services like daily aspirin use, and tobacco-cessation and alcohol-abuse screening could save 2 million lives and nearly $4 billion annually, according to the National Commission on Prevention Priorities.
It’s alive! Scientific rebel J. Craig Venter created headlines — and drew comparisons to Dr. Frankenstein — when he said in May that his team had created what could be considered the first synthetic living creature, the New York Times writes.
